In RA, the discontinuation rate of TNF antagonists in the first year of treatment is higher more recently than a decade ago, inefficacy being the main reason for the increased rate.
The rate of discontinuation for adverse events has remained stable.
2012-02-08
Eng.
Annals of the rheumatic diseases
Rheumatology Department, Hospital Clínico Universitario, Santiago de Compostela, Spain. juan.gomez-reino.carnota [at] sergas.es
Ann Rheum Dis. 2012 Mar;71(3):382-5
© Galenicom 1999-2013